3D cell culture has gained increasing attention in recent years as a method for studying cells in an environment that more accurately mimics the tissue structure in vivo. However, constructing 3D models requires scaffolds and matrices that support cell growth, and the dispensing of these materials poses challenges, leading to issues with reproducibility and efficiency. To address these challenges, PeptiMatrix Ltd. collaborated with SPT Labtech to evaluate the dispensing performance of PeptiMatrix hydrogel matrices using the dragonfly discovery liquid dispensing system. This study presents an integrated approach to achieving high-throughput, cost-effective, and reproducible 3D cell culture assays, and discusses how this can accelerate advancements in drug discovery and research.

The Norwegian Sequencing Centre (NSC), located at Oslo University Hospital, has recognized the importance of lab automation in fields such as proteomics and genomics through practical experience. Recently, they have implemented liquid handling solutions, including our firefly system, significantly improving workflows to address daily operations and high-throughput challenges. These automations have enhanced work efficiency, optimized reagent usage, and reduced the risk of errors. In NSC's automation efforts, the following factors were key selection criteria: - Cost - Efficiency - Usability - Service support Considering various other conditions, our system was adopted as the most suitable for the automated workflow. It is believed that the importance of automation will continue to grow, becoming an essential element for core facilities. NSC's initiatives are expected to serve as a reference for other research institutions and as a model for maximizing the benefits of automation. For detailed news, please refer to the articles linked.

- Screening of tuberculosis treatment drugs using the latest automation technology - Identification of promising enzyme inhibitors through the evaluation of 6,000 compounds - Confirmation of the effectiveness of automation systems in streamlining the drug discovery process - Contribution to the development of new treatment methods for drug-resistant tuberculosis In research aimed at the novel development of tuberculosis treatment drugs, a collaborative study was conducted by SPT Labtech, Automata, GSK, and the Francis Crick Institute. Utilizing the latest automation technology, large-scale screening targeting key metabolic pathways of the tuberculosis bacterium was carried out. In particular, the efficacy, selectivity, and microbiological effectiveness of 6,000 compounds were evaluated. This initiative accelerated the identification of promising enzyme inhibitors and established a foundation for further drug discovery chemistry research. Additionally, important insights were gained regarding the potential integration of robotic platforms in high-throughput drug discovery through improvements in the automated workflow. This research represents a significant step in the development of new treatment methods in response to the increasing challenge of drug-resistant tuberculosis.

Announcement of a webinar for researchers in the pharmaceutical and biotechnology industries, as well as academia, interested in proteomics and multi-omics. Title: "Advanced proteomic biomarker discovery for understanding disease pathophysiology" Speakers: Eric Schordan, PhD and Kamila Koprowska, PhD Overview: How large-scale proteomics data generation, integrating the Olink Explore platform and positive displacement liquid handling technology, provides deep insights into the pathophysiological mechanisms underlying various drugs and diseases, and how it offers a comprehensive reading of protein expression levels in biological samples.

Identifying early markers of transition between human health and disease is a key objective of systems medicine. This strategy requires the collection of diverse longitudinal data from each individual before and after symptoms appear. However, until recently, the comprehensive collection of plasma proteomics has been a barrier to this. In this webinar, we will discuss how high-throughput and high-sensitivity protein profiling, combining Olink technology with SPT Labtech's liquid handling automation technology, has resolved this bottleneck. - The importance of longitudinal deep phenotyping, including plasma proteomics, in systems medicine, complex disease research, and biomarker discovery. - The significance of establishing reference values and ranges for normal human plasma. - How potential prognostic markers for severe and "long" COVID-19 were identified from the plasma proteome. - How adopting the bundled infrastructure of Olink and SPT Labtech enables high throughput and uncompromised data quality in genomics, single-cell, RNA sequencing, and more.